Sequoia Financial Advisors LLC Acquires 5,485 Shares of GSK plc (NYSE:GSK)

Sequoia Financial Advisors LLC boosted its holdings in GSK plc (NYSE:GSK) by 35.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,177 shares of the pharmaceutical company’s stock after acquiring an additional 5,485 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in GSK were worth $785,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. FinTrust Capital Advisors LLC lifted its holdings in shares of GSK by 6.9% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock valued at $158,000 after buying an additional 281 shares during the period. UMB Bank n.a. lifted its holdings in shares of GSK by 4.8% during the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock valued at $234,000 after buying an additional 297 shares during the period. Fiduciary Group LLC lifted its holdings in shares of GSK by 3.3% during the 1st quarter. Fiduciary Group LLC now owns 9,367 shares of the pharmaceutical company’s stock valued at $342,000 after buying an additional 300 shares during the period. KCS Wealth Advisory lifted its holdings in shares of GSK by 1.5% during the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock valued at $775,000 after buying an additional 314 shares during the period. Finally, BSW Wealth Partners lifted its holdings in shares of GSK by 5.2% during the 1st quarter. BSW Wealth Partners now owns 6,345 shares of the pharmaceutical company’s stock valued at $226,000 after buying an additional 316 shares during the period. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Morgan Stanley assumed coverage on GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

GSK Trading Down 0.4 %

NYSE:GSK opened at $40.50 on Tuesday. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. The firm has a market capitalization of $83.93 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 1.86 and a beta of 0.64. GSK plc has a one year low of $33.33 and a one year high of $43.84. The business has a fifty day moving average price of $42.07 and a 200-day moving average price of $38.73.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The company had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Sell-side analysts forecast that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a dividend of $0.3564 per share. This is a positive change from GSK’s previous quarterly dividend of $0.34. The ex-dividend date was Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.52%. GSK’s dividend payout ratio (DPR) is presently 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.